deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00095940

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Childhood Anaplastic Astrocytoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Ependymoma Recurrent Childhood Giant Cell Glioblastoma Recurrent Childhood Glioblastoma Recurrent Childhood Gliosarcoma Recurrent Childhood Medulloblastoma Recurrent Childhood Oligodendroglioma
Interventions laboratory biomarker analysis lapatinib ditosylate magnetic resonance imaging pharmacological study positron emission tomography therapeutic conventional surgery
Updated 7 times since 2017 Last updated: May 7, 2014 Started: Oct 31, 2004 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Recurrent Childhood Anaplastic Astrocytoma and Recurrent Childhood Brain Stem Glioma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations